Frontiers in Psychiatry
November 6, 2026
Christopher W. T. Miller
As technological advances have occurred in medicine, including improvements in rates of resuscitation, descriptions of near-death experiences (NDEs) have increased significantly. However, NDEs have been present within religious, literary, and biographical texts for centuries. The phenomenology of NDEs encompasses an inward journey wherein review of one’s life, seeing the dead, and an encounter...
Frontiers in Psychiatry
November 6, 2026
Liang Lv, Xiao-Yu Zhang
Nitrous oxide (N 2 O) abuse has emerged as an increasingly serious public health concern, yet effective interventions for N 2 O dependence remain lacking. We report on a 21-year-old woman with N 2 O dependence who, after 6 months of repeated N 2 O inhalation, developed gait instability, limb numbness and tremors, accompanied by delusions and auditory hallucinations. During her first...
Frontiers in Psychiatry
November 2, 2026
Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.
Background: Duration of untreated psychosis (DUP) is an established prognostic factor in first-episode psychosis, and cannabis use is highly prevalent in these populations, yet whether and in which direction the two are related remains unclear. Objective: To review the evidence on cannabis use and DUP in first-episode psychosis, with attention to how exposure and outcome have been defined....
Frontiers in Psychiatry
October 30, 2026
Valerio Ricci, Domenico de Berardis, Giuseppe Maina et al.
Cannabis is the most widely used psychoactive substance subject to legal restriction worldwide, and one of its best-characterized acute effects is a distortion of the lived sense of time: users reliably report that time slows, fragments, or loses its ordinary continuity, an effect documented since the earliest controlled studies of marijuana intoxication and confirmed across decades of...
Frontiers in Psychiatry
October 28, 2026
Maria Åkesson, Pehr Granqvist, Robert Johansson et al.
BackgroundPsychedelic retreats are increasingly used to promote wellbeing outside clinical settings, yet the psychological processes associated with sustained improvements in wellbeing remain poorly understood. From a public mental health perspective, identifying mechanisms that support positive mental health beyond symptom reduction is of growing importance.MethodsThis naturalistic...
Frontiers in Psychiatry
October 21, 2026
Hong Liu, Bao‐Liang Zhong
Background Religious and spiritual practices are increasingly recognised as complementary approaches for managing severe mental illnesses, but their use among patients with schizophrenia in China remains poorly understood. Objectives To investigate religious affiliation, religious, spiritual, or folk healing practices, perceived helpfulness, and associated factors among Chinese patients with...
Frontiers in Psychiatry
October 16, 2026
Gilberto Sousa Alves, Humberto M. M. Dos Santos, Samira D Damasceno et al.
Background Esketamine is a promising therapeutic option for treatment-resistant depression (TRD). Intravenous (IV) administration is the most extensively studied parenteral route. However, subcutaneous (SC) administration may offer simpler, more scalable delivery. Multicenter real-world evidence comparing IV and SC routes of administration remains limited. Objective To report clinical outcomes...
Frontiers in Psychiatry
October 14, 2026
How does the brain transform a chaotic stream of sensory signals into a stable, shared experience of reality? This theoretical paper proposes that the brain does not passively receive the world, but actively projects it – it continuously generates predictions about sensory inputs and updates its internal model when predictions fail, a process formally described by the free energy principle and...
Frontiers in Psychiatry
October 14, 2026
Mathieu Seynaeve, Leonie Schneider, Ian Roullier et al.
BackgroundWhile psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants’ experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery.MethodsThis qualitative descriptive study, informed...
Frontiers in Psychiatry
October 8, 2026
Anthony L. Back, Cynthia J. Price, Bonnie A. Mcgregor et al.
Cancer patients arrive for psilocybin therapy with bodies altered by illness and treatment — bodies that they have learned to brace against, dissociate from, or scan for threat. Research on psilocybin-assisted therapy for cancer-related depression and anxiety consistently identifies the quality of the acute subjective experience — reflected in constructs such as acceptance, surrender,...
Frontiers in Psychiatry
October 5, 2026
Andreas Paris, Foteini Thoma, Aikaterini Velentza et al.
Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and...
Frontiers in Psychiatry
October 1, 2026
Matthew M. Kinney, Zackary L. Bowers
Ketamine has progressed from solely being an anesthetic agent to a drug of rising clinical and research interest due to its distinctive pharmacological properties. Its dissociative properties and rapid-acting antidepressant effects have made it a prominent area of investigation across many medical and psychiatric applications. This systematic review examines ketamine’s history, mechanisms of...
Frontiers in Psychiatry
September 30, 2026
Yani Duan, Nor Akmar Nordin, Siti Aisyah Panatik et al.
Mindfulness training holds unique value in enhancing decision-making, particularly under uncertainty. Against the backdrop of Chinese fresh graduates facing mounting employment pressure, widened wealth gaps, and a heightened tendency for high-risk decisions, this study draws on Risk Sensitivity Theory (RST) and the Self-Control Resource Model (SCM). Employing a 2×2 mixed experimental design, it...
Frontiers in Psychiatry
September 29, 2026
Naoyuki Katagiri, Hiromi Tagata, Takashi Uchino et al.
Background In psychopathology, schizophrenia has been understood as a disorder characterized by disturbances in subjective consciousness. Subjective consciousness and its relationship to interactions between internal representations and external events have been discussed in phenomenology. Recent computational neuroscience conceptualizes the brain as an inferential system that minimizes...
Frontiers in Psychiatry
September 28, 2026
You Tongyang, Qin Li, Yao Fu et al.
Background Emergence delirium (ED) is a prevalent and complex complication in the post-anesthesia care unit (PACU) that significantly impacts patients undergoing radical lung cancer surgery. Despite its high incidence, the subjective experience of ED, along with patients’ coping strategies and support needs, remains insufficiently understood. This study aims to address this gap by exploring the...
Frontiers in Psychiatry
September 24, 2026
Franziska Stadler, Johan Saelens, Ioline D. Henter et al.
Background: The past few decades have seen a revived interest in psychedelic-assisted and ketamine-assisted therapy for mental health disorders, but data concerning the acute, subacute, and long-term effects of serotonergic psychedelics on cognitive functioning are scarce. This international, online study (N = 759) sought to investigate the potential acute, subacute, and long-term effects of...
Frontiers in Psychiatry
September 21, 2026
Phil Wolfson, Cody Carroll
Introduction Ketamine Assisted Psychotherapy (KAP) is a developing modality with broad impact on humans suffering with a variety of emotional and relationship difficulties that encompass many diagnostic entities. Our application of KAP has extended to and included the treatment of adolescents and young adults in a family therapy format. Given the increasing scope and complexity of the...
Frontiers in Psychiatry
September 16, 2026
Fang Shen, Hui Zhou, Tongming Zhang
Background and objective Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. Although mindfulness-based interventions (MBIs) have been proposed as promising non-pharmacological treatments, evidence regarding their efficacy in children and adolescents with ADHD remains inconsistent. Methods A systematic search of PubMed, Embase, the Cochrane...
Frontiers in Psychiatry
September 15, 2026
Serena Chiara Civardi, Filippo Besana, Federico Durbano et al.
Background Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for...
Frontiers in Psychiatry
September 3, 2026
Anita Słupska, Wiesław Jerzy Cubała, Damian Swieczkowski et al.
Objectives Ketamine and esketamine are increasingly used for treatment-resistant depressive disorders, particularly when rapid symptom reduction is clinically desirable. Intranasal esketamine has a product-specific regulatory framework in several jurisdictions, whereas most racemic ketamine formulations remain off-label for psychiatric indications. This narrative review provides practical...
Frontiers in Psychiatry
September 3, 2026
Mary R. Shen, Kwadwo Owusu-Boaitey, Zackari D. Murphy et al.
IntroductionOpioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor.MethodsWe conducted a...
Frontiers in Psychiatry
September 1, 2026
Gabrielle Agin-Liebes, Sarah Shnayder, Geena Fram et al.
Introduction Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders. Materials and methods A qualitative case comparison was conducted using...
Frontiers in Psychiatry
August 26, 2026
Jon Berner
Background Multiple preclinical and clinical reports suggest that rapamycin augmentation may increase the safety and efficacy of ketamine treatment. Population variability in patient biochemical gain-of-function and phenotypic admixtures, however, has slowed initial investigations into patient selection and dose finding. Methods A single-center, retrospective chart review identified 101...
Frontiers in Psychiatry
August 19, 2026
Alan Maddock, Thearith Heang, Nil Ean et al.
Objectives Mindfulness is increasingly used in global mental health, yet its measurement tools are largely developed within Western cultural frameworks. This study aimed to (1) translate and culturally adapt the Southampton Mindfulness Questionnaire (SMQ) into Khmer, (2) evaluate its cultural integrity among Cambodian adults with physical disabilities, and (3) examine the psychometric...
Frontiers in Psychiatry
August 19, 2026
Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.
IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...